Language Settings
Select Website Language

GDPR Compliance

We use cookies to ensure you get the best experience on our website. By continuing to use our site, you accept our use of cookies, Privacy Policy, and Terms of Service.

India Targets $300 Billion Bioeconomy by 2030, Says Science Minister

2 hours ago

6

0

India's Biotechnology Research and Innovation Council aims to expand the national bioeconomy to $300 billion by 2030 and $1 trillion by 2047.

By News National Editorial Team

India is aiming to expand its bioeconomy to $300 billion by 2030 and $1 trillion by 2047, according to Union Science and Technology Minister Jitendra Singh.

The announcement highlights the government's ambition to strengthen biotechnology research, innovation and commercial applications across the country.

The Biotechnology Research and Innovation Council (BRIC) is expected to play an important role in supporting this objective.

Biotechnology creates new economic opportunities

Biotechnology has applications across healthcare, agriculture, industrial manufacturing and environmental protection.

Important areas include vaccine development, advanced medicines, genetic research, agricultural biotechnology and bio-based manufacturing.

Opportunities for Indian startups

India has an opportunity to develop biotechnology companies that can serve domestic and international markets.

Startups working in diagnostics, medical research, pharmaceutical development and agricultural innovation could benefit from stronger research infrastructure.

Challenges ahead

Achieving the targets will require sustained investment, skilled researchers, intellectual-property protection, industry partnerships and access to advanced laboratories.

Source: Akashvani News,

Click here to Read More
Previous Article
A magnitude 6.7 earthquake strikes near Ondores in Peru's Junín region
Next Article
Bullet Train Project: Power Supply Begins on 50-km Surat–Bilimora Section

Related India Updates:

Are you sure? You want to delete this comment..! Remove Cancel

Comments (0)

    Leave a comment